 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 August 1996 | Volume 125 Issue 4 | Pages 300-303
Objective: To compare the operating characteristics of two tests for diagnosing pheochromocytoma: 1) measurement of the ratio between urinary metanephrine and creatinine levels and 2) measurement of urinary metanephrine levels alone. A second objective was to ascertain the reasons for false-positive test results.
Design: Cross-sectional study.
Setting: Hypertension referral center.
Patients: 1013 patients referred for hypertension and tested for pheochromocytoma.
Measurements: 24-hour urinary levels of metanephrine (measured using liquid chromatography) and creatinine. The presence of pheochromocytoma was confirmed at surgery. In patients with positive test results, the absence of pheochromocytoma was documented by negative results of retests and imaging procedures.
Results: Of 58 patients with increased metanephrine levels or increased metanephrine-to-creatinine ratios, 20 had pheochromocytoma and 38 did not. Of the 38 patients without pheochromocytoma, 15 had high metanephrine levels but normal metanephrine-to-creatinine ratios. The respective operating characteristics of measurement of urinary metanephrine levels and measurement of the metanephrine-to-creatinine ratio were as follows: sensitivity, 95% and 100%; specificity, 98% and 98%; positive predictive value, 46% and 47%; and negative predictive value, 100% and 100%. In 13 of the 23 patients who had a high metanephrine-to-creatinine ratio, various acute events may have caused hypersecretion of catecholamines.
Conclusions: Measurement of the metanephrine-to-creatinine ratio is a sensitive and specific test for pheochromocytoma. However, acute events may increase urinary metanephrine excretion to the level that occurs with tumors.
Author and Article Information
From Hopital Broussais, Paris, France.
BRIEF COMMUNICATION
The Urinary Metanephrine-to-Creatinine Ratio for the Diagnosis of Pheochromocytoma
Requests for Reprints: Pierre-Francois Plouin, MD, Hopital Broussais, 96 rue Didot, 75674 Paris Cedex 14, France.
Current Author Addresses: Drs. Heron, Chatellier, Billaud, Foos, and Plouin: Hopital Broussais, 96 rue Didot, 75674 Paris Cedex 14, France.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  L. Amar, E. Baudin, N. Burnichon, S. Peyrard, S. Silvera, J. Bertherat, X. Bertagna, M. Schlumberger, X. Jeunemaitre, A.-P. Gimenez-Roqueplo, et al. Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3822 - 3828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Intenzo, S. Jabbour, H. C. Lin, J. L. Miller, S. M. Kim, D. M. Capuzzi, and E. P. Mitchell Scintigraphic Imaging of Body Neuroendocrine Tumors RadioGraphics, September 1, 2007; 27(5): 1355 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Amar, A. Servais, A.-P. Gimenez-Roqueplo, F. Zinzindohoue, G. Chatellier, and P.-F. Plouin Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2110 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A A Syed, H A Wheatley, M N Badminton, and I F W McDowell Urinary catecholamines and metabolites in the immediate postoperative period following major surgery J. Clin. Pathol., May 1, 2004; 57(5): 548 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Favier, P.-F. Plouin, P. Corvol, and J.-M. Gasc Angiogenesis and Vascular Architecture in Pheochromocytomas : Distinctive Traits in Malignant Tumors Am. J. Pathol., October 1, 2002; 161(4): 1235 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. M. Lenders, K. Pacak, M. M. Walther, W. M. Linehan, M. Mannelli, P. Friberg, H. R. Keiser, D. S. Goldstein, and G. Eisenhofer Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best? JAMA, March 20, 2002; 287(11): 1427 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-F. Plouin, J.-M. Duclos, F. Soppelsa, G. Boublil, and G. Chatellier Factors Associated with Perioperative Morbidity and Mortality in Patients with Pheochromocytoma: Analysis of 165 Operations at a Single Center J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1480 - 1486. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. M. Witteles, E. L. Kaplan, and M. F. Roizen Sensitivity of Diagnostic and Localization Tests for Pheochromocytoma in Clinical Practice Arch Intern Med, September 11, 2000; 160(16): 2521 - 2524. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Eisenhofer, J. W.M. Lenders, W. M. Linehan, M. M. Walther, D. S. Goldstein, and H. R. Keiser Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2 N. Engl. J. Med., June 17, 1999; 340(24): 1872 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Eisenhofer, H. Keiser, P. Friberg, E. Mezey, T.-T. Huynh, B. Hiremagalur, T. Ellingson, S. Duddempudi, A. Eijsbouts, and J. W. M. Lenders Plasma Metanephrines Are Markers of Pheochromocytoma Produced by Catechol-O-Methyltransferase Within Tumors J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2175 - 2185. [Abstract] [Full Text]
|
|
|
|
 |
|
 P.-F. Plouin, G. Chatellier, I. Fofol, and P. Corvol Tumor Recurrence and Hypertension Persistence After Successful Pheochromocytoma Operation Hypertension, May 1, 1997; 29(5): 1133 - 1139. [Abstract] [Full Text]
|
|
Article
